問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
蔡孟耘
下載
2025-10-01 - 2032-01-31
Condition/Disease
Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment
Test Drug
Telisotuzumab Adizutecan (ABBV-400)
Participate Sites8Sites
Recruiting8Sites
2021-08-19 - 2022-03-30
Participate Sites5Sites
Recruiting5Sites
2026-03-16 - 2029-01-31
Participate Sites12Sites
Not yet recruiting2Sites
Recruiting10Sites
2025-06-01 - 2028-12-31
Participate Sites10Sites
2023-09-01 - 2029-12-31
Participate Sites13Sites
Recruiting13Sites
2023-08-31 - 2032-02-12
Participate Sites6Sites
Not yet recruiting4Sites
Recruiting2Sites
2026-03-01 - 2041-12-31
2026-02-26 - 2028-04-30
Not yet recruiting1Sites
Recruiting7Sites
2020-06-20 - 2027-12-31
Not yet recruiting3Sites
Recruiting9Sites
Terminated1Sites
2024-09-16 - 2027-09-24
Participate Sites7Sites
全部
